damsin: from Ambrosia maritima; structure
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Ambrosia | genus | A plant genus of the family ASTERACEAE. The POLLEN is one cause of HAYFEVER.[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 14631 |
CHEMBL ID | 2286469 |
CHEBI ID | 4314 |
SCHEMBL ID | 18642932 |
MeSH ID | M0059184 |
Synonym |
---|
azuleno(4,5-b)furan-2,9-dione, decahydro-6,9a-dimethyl-3-methylene-, (3as-(3aalpha,6beta,6aalpha,9abeta,9balpha))- |
decahydro-6,9a-dimethyl-3-methylene-azuleneo(4,5-b)furan-2,9-dione |
10-alpha-h-ambros-11(13)-en-12-oic acid, 6-beta-hydroxy-4-oxo-, gamma-lactone |
10alphah-ambros-11(13)-en-12-oic acid, 6beta-hydroxy-4-oxo-, gamma-lactone |
azulene derivative |
nsc-85249 |
azuleno[4,9-dione, decahydro-6,9a-dimethyl-3-methylene-, [3as-(3a.alpha.,6.beta.,6a.alpha.,9a.beta.,9b.alpha.)]- |
10.alpha.h-ambros-11(13)-en-12-oic acid, .gamma.-lactone |
1216-42-8 |
damsin |
C09386 |
(3as,6s,6as,9ar,9br)-6,9a-dimethyl-3-methylidene-3a,4,5,6,6a,7,8,9b-octahydroazuleno[8,7-b]furan-2,9-dione |
chebi:4314 , |
CHEMBL2286469 |
SCHEMBL18642932 |
DTXSID70923878 |
6,9a-dimethyl-3-methylidenedecahydroazuleno[4,5-b]furan-2,9-dione |
Q27106332 |
Damsin and ambrosin treatment increased the number of micronuclei. Another sign of DNA damage was the increased level of p53. Treatment decreased the CSC subpopulation and inhibited cell migration.
Excerpt | Reference | Relevance |
---|---|---|
"Damsin and ambrosin treatment increased the number of micronuclei; moreover, another sign of DNA damage was the increased level of p53." | ( Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative. Almanza, G; Huang, X; Kempengren, S; Malakpour, A; Oredsson, S; Rodrigo, G; Smiljanic, S; Sotillo, WS; Sterner, O; Villagomez, R, 2017) | 1.18 |
"Treatment with damsin and ambrosin decreased the CSC subpopulation and inhibited cell migration." | ( Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative. Almanza, G; Huang, X; Kempengren, S; Malakpour, A; Oredsson, S; Rodrigo, G; Smiljanic, S; Sotillo, WS; Sterner, O; Villagomez, R, 2017) | 0.79 |
Excerpt | Relevance | Reference |
---|---|---|
" Inhibitory concentration 50 (IC50) values were obtained from dose-response curves." | ( Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative. Almanza, G; Huang, X; Kempengren, S; Malakpour, A; Oredsson, S; Rodrigo, G; Smiljanic, S; Sotillo, WS; Sterner, O; Villagomez, R, 2017) | 0.46 |
Class | Description |
---|---|
sesquiterpene lactone | Any member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |